← Alle mensen

RB

Remy B Verheijen

3 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-smal...

European journal of cancer (Oxford, England : 1990) · 9 september 2025

Subcutaan versus IV amivantamab plus lazertinib bij EGFR-gemuteerd NSCLC: PALOMA-3

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 oktober 2024

Savolitinib versus sunitinib bij MET-gedreven papillair RCC: SAVOIR fase III

JAMA oncology · 1 augustus 2020